B&L Sees Visudyne Coverage Loss As Envision Gain; Market Rebound In Sight
This article was originally published in The Gray Sheet
Executive SummaryBausch & Lomb views CMS' decision not to cover QLT's Visudyne for age-related macular degeneration in patients with occult lesions as a net positive for the company, which is developing a treatment of its own
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.